Jason Berner, MD
Endocrinology, Diabetes & Metabolism · Jasper, GANPI 1144201781
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $362,393 of the $457,107 with a category attached, or 79.3%. Lilly USA, LLC accounts for 63.8% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $171,246 and has fallen 85.9% since, to $24,063 in 2025. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,850 payments — averaging $247.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$292K
- Amarin Pharma, Inc.$33K
- AstraZeneca$30K
- Boehringer Ingelheim$27K
- Dexcom, Inc.$23K
- Abbott$22K
- plus $31K from 54 others
Across 419 payments — averaging $5210.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$411K
- Merck$404K
- AbbVie$306K
- Eli Lilly$280K
- Insulet Corporation$218K
- Alnylam Pharmaceuticals Inc.$215K
- plus $349K from 7 others
What the payments were for
- Consulting fees$12,1803%
- Speaking & faculty fees$362,39379%
- Travel & lodging$51,97311%
- Food & beverage$30,2017%
- Education$3010%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$113,829
- MOUNJARO$99,450
- JARDIANCE$61,959
- Vascepa$30,959
- FARXIGA$27,395
- DEXCOM G7 GSS (161)$22,191
- DEXCOM STELO GLUCOSE BIOSENSOR$16,419
- FreeStyle Libre Pro$11,897
- Synthroid$6,476
- FREESTYLE LIBRE 3$6,299
- Tirosint$3,000
- FreeStyle Libre 2$2,846
- DISEASE STATE$2,652
- INVOKANA$2,462
- UNITHROID$600
- Korlym$457
- UNITY DIABETES MANAGEMENT SYSTEM$450
- TEPEZZA$265
- GVOKE PFS$236
- CeQur Simplicity$212
How this compares
$457,107 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 257 | $345,195 |
| MounjaroTirzepatide | 217 | $244,302 |
| JardianceEmpagliflozin | 134 | $132,291 |
| TrulicityDulaglutide | 98 | $102,860 |
| FarxigaDapagliflozin Propanediol | 74 | $83,750 |
| VascepaIcosapent Ethyl | 110 | $79,355 |
| JanuviaSitagliptin Phosphate | 50 | $53,669 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 52 | $50,387 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 49 | $42,649 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $37,447 |
| InvokanaCanagliflozin | 37 | $32,913 |
| Tresiba Flextouch U-100Insulin Degludec | 59 | $28,563 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 31 | $27,775 |
| SynthroidLevothyroxine Sodium | 271 | $27,200 |
| LyumjevInsulin Lispro-Aabc | 15 | $25,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $291,789 | $395,361417 claims |
| Novo NordiskOzempic, Novolog | $2,125 | $348,966275 claims |
| Boehringer IngelheimJardiance | $27,140 | $132,291134 claims |
| AstraZenecaFarxiga | $29,531 | $83,75074 claims |
| MerckJanuvia | $555 | $53,66950 claims |
| Johnson & JohnsonInvokana | $2,569 | $32,91337 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $4,719 | $27,77531 claims |
| AbbVieSynthroid | $6,914 | $27,200271 claims |
| BayerKerendia | $410 | $7,84612 claims |
| Cequr CorporationCequr Simplicity | $326 | $6,60513 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $1,737 | $3,708160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Jasper
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
- Naland ShenoySnellville$139K
- David ShoreLawrenceville$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.